All News

Sequential therapy of ranibizumab and a dexamethasone implant improved results in macular edema secondary to non–ischemic retinal vein occlusion.

JoAnn Manson, MD, shares findings from the VIVID trial on vitamin D, the timing of use, and its potential to reduce long COVID risk and symptom severity.

ACIP changes threaten vaccine coverage and raise costs, according to a roundtable of experts warning of widening disparities and long-term public health risks.

New evidence affirms hepatitis B birth-dose safety as the CDC makes it optional.

Strength and aerobic training improves cardiorespiratory fitness, functional capacity, and muscle strength more than aerobic exercise alone in heart failure.

Global pediatric HIV data show dolutegravir links to early modest weight gain that plateaus by year 2, easing concerns and highlighting regional nutrition gaps.

Despite decreases in therapy use, hospitalizations for multiple sclerosis and neurologist visits were not affected significantly.

A study suggests vitamin D may reduce long COVID symptoms at 8 weeks, although larger trials are needed to confirm benefits and optimal timing, explains JoAnn E. Manson, MD, MPH, DrPH.

The cap cut quarterly spending by the hundreds and lowered A1c levels but failed to expand the pool of insulin users.

From teledermatology billing to rural outreach and transplant advances, new studies and presentations reveal shifts in access, equity, and patient outcomes.

Proactive adverse effect management helps patients with skin cancer stay on treatment longer, according to Todd Schlesinger, MD.

A new study suggests that incorporating proteomic data can help refine risk stratification in mantle cell lymphoma (MCL).

Zanubrutinib had low discontinuation and atrial fibrillation rates in R/R CLL/SLL, supporting tolerability over first-generation BTK inhibitors.

Learn how CRS and ICANS present in patients undergoing immunotherapy and what clinicians should know about recognizing and managing these toxicities.

Mammography use fell significantly among younger, uninsured, and non-Hispanic White and Asian women from 2002-2022, with the 2009 USPSTF guideline change a likely driver.

Continuing conversations from last year, experts at the AAD Annual Meeting in Denver weighed the pros and cons of teledermatology and AI.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The FDA's March 2026 approvals marked significant regulatory milestones across multiple disease states.

Attempts to refine non–small cell lung cancer treatment selection have been limited by a lack of biomarkers, but recent research is expanding the potential landscape.

Adults can undergo CAR T-cell therapy for relapsed or refractory mantle cell lymphoma after the full approval of the treatment.

The US has seen approximately 370 cases of mpox through March 2026, indicating a consistent need to diagnose the illness.

A global cohort has tracked pediatric HIV growth after dolutegravir, showing early catch-up weight gain, then stable BMI without long-term obesity risk.

Evaluation of more than 65,000 trials and 350,000 investigator sites highlights significant exposure in oncology and late-stage development.

Chronic skin diseases are increasingly being understood as systemic conditions driven by the interconnected brain-gut-skin axis.

FDA approves Eli Lilly's orforglipron (Foundayo), the first GLP-1 obesity pill with no food or water restrictions.

The FDA now permits outpatient monitoring for epcoritamab’s first full dose in R/R DLBCL, as EPCORE-NHL-6 data support safe bispecific antibody access.

New real-world data highlight sustained response and remission rates with esketamine nasal spray for patients with treatment-resistant depression.

Novo Nordisk launches a Wegovy subscription program to reduce costs, expand access, and improve long-term adherence.